Imbruvica Gets Broad CLL Okay in EU But Draft Rebuff From UK's NICE
Executive Summary
AbbVie Inc. and Johnson & Johnson's Imbruvica (ibrutinib) has won a broader chronic lymphocytic leukemia (CLL) label in Europe but given a draft rebuff from NICE due to data ambiguity and told instead to file for inclusion in the UK's controversial government-funded Cancer Drugs Fund.
You may also be interested in...
NICE Backs Imbruvica In CLL On Price Cut Despite Outcome Uncertainties
It looks likely AbbVie. and Johnson & Johnson's Imbruvica (ibrutinib) will be made routinely available on the NHS in England and Wales for treating chronic lymphocytic leukemia after an undisclosed price cut was offered and data further considered by the UK HTA NICE.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.